Published in Malar J on July 08, 2004
HIV impairs opsonic phagocytic clearance of pregnancy-associated malaria parasites. PLoS Med (2007) 1.49
High levels of antibodies to multiple domains and strains of VAR2CSA correlate with the absence of placental malaria in Cameroonian women living in an area of high Plasmodium falciparum transmission. Infect Immun (2012) 1.15
High avidity antibodies to full-length VAR2CSA correlate with absence of placental malaria. PLoS One (2012) 1.09
Anti-malarial IgG subclasses pattern and FcγRIIa (CD32) polymorphism among pregnancy-associated malaria in semi-immune Saudi women. Malar J (2013) 0.79
Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science (1996) 10.03
An analysis of malaria in pregnancy in Africa. Bull World Health Organ (1983) 6.09
Maternal antibodies block malaria. Nature (1998) 5.67
Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat Med (1998) 5.41
Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Med Hyg (1990) 4.70
Antigenic variation at the infected red cell surface in malaria. Annu Rev Microbiol (2001) 4.12
Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg (1998) 3.74
Vector density gradients and the epidemiology of urban malaria in Dakar, Senegal. Am J Trop Med Hyg (1992) 3.71
Chondroitin sulfate A is a cell surface receptor for Plasmodium falciparum-infected erythrocytes. J Exp Med (1995) 3.46
Comparison of methods for the rapid laboratory assessment of children with malaria. Am J Trop Med Hyg (2001) 3.44
Adhesion of Plasmodium falciparum-infected erythrocytes to hyaluronic acid in placental malaria. Nat Med (2000) 3.40
Epidemiology, malaria and pregnancy. Am J Trop Med Hyg (1984) 3.32
Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet (2004) 3.25
Antibodies that inhibit Plasmodium falciparum adhesion to chondroitin sulfate A are associated with increased birth weight and the gestational age of newborns. Infect Immun (2003) 3.05
Detection of antibodies to variant antigens on Plasmodium falciparum-infected erythrocytes by flow cytometry. Cytometry (1999) 2.87
Role of nonimmune IgG bound to PfEMP1 in placental malaria. Science (2001) 2.50
An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. Ann Trop Med Parasitol (1998) 2.30
Gravidity-dependent production of antibodies that inhibit binding of Plasmodium falciparum-infected erythrocytes to placental chondroitin sulfate proteoglycan during pregnancy. Infect Immun (2001) 1.82
Antibodies to variant surface antigens of Plasmodium falciparum-infected erythrocytes and adhesion inhibitory antibodies are associated with placental malaria and have overlapping and distinct targets. J Infect Dis (2004) 1.63
Development of antibodies against chondroitin sulfate A-adherent Plasmodium falciparum in pregnant women. Infect Immun (1999) 1.41
An assessment of low birthweight risk in primiparae as an indicator of malaria control in pregnancy. Int J Epidemiol (1991) 1.35
Ex vivo desequestration of Plasmodium falciparum-infected erythrocytes from human placenta by chondroitin sulfate A. Infect Immun (1999) 1.29
PCR typing of Plasmodium falciparum in matched peripheral, placental and umbilical cord blood. Parasitol Res (2002) 1.19
Variants of Plasmodium falciparum erythrocyte membrane protein 1 expressed by different placental parasites are closely related and adhere to chondroitin sulfate A. J Infect Dis (2001) 1.02
Amplification of cytoadherence in cerebral malaria: towards a more rational explanation of disease pathophysiology. Ann Trop Med Parasitol (1993) 1.02
Characterization and localization of Plasmodium falciparum surface antigens on infected erythrocytes from west African patients. Blood (1991) 0.95
Monocyte activation and T cell inhibition in Plasmodium falciparum-infected placenta. J Infect Dis (2004) 0.92
Human antibody responses to Pfs 230, a sexual stage-specific surface antigen of Plasmodium falciparum: non-responsiveness is a stable phenotype but does not appear to be genetically regulated. Parasite Immunol (1994) 0.90
Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol (2003) 6.04
Allergy, parasites, and the hygiene hypothesis. Science (2002) 5.01
Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med (2004) 4.76
Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis (2007) 3.88
Plasmodium falciparum associated with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes. J Exp Med (2004) 3.63
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infect Dis (2013) 3.46
Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet (2004) 3.25
Short report: Piloting paperless data entry for clinical research in Africa. Am J Trop Med Hyg (2005) 2.85
Placental malaria increases malaria risk in the first 30 months of life. Clin Infect Dis (2008) 2.69
Amplification of Plasmodium falciparum multidrug resistance gene 1 in isolates from Gabon. J Infect Dis (2005) 2.58
Plasmodium falciparum variant surface antigen expression varies between isolates causing severe and nonsevere malaria and is modified by acquired immunity. J Immunol (2002) 2.39
Severe falciparum malaria in Gabonese children: clinical and laboratory features. Malar J (2005) 2.35
Fosmidomycin for malaria. Lancet (2002) 2.03
Malaria-induced acquisition of antibodies to Plasmodium falciparum variant surface antigens. Infect Immun (2002) 2.00
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial. J Infect Dis (2007) 1.99
High level of var2csa transcription by Plasmodium falciparum isolated from the placenta. J Infect Dis (2005) 1.90
Microscopic and sub-microscopic Plasmodium falciparum infection, but not inflammation caused by infection, is associated with low birth weight. Am J Trop Med Hyg (2006) 1.88
Congenital parasitic infections: a review. Acta Trop (2011) 1.88
Long-term treatment of intestinal helminths increases mite skin-test reactivity in Gabonese schoolchildren. J Infect Dis (2004) 1.85
Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam. Hepatology (2006) 1.82
Influence of the timing of malaria infection during pregnancy on birth weight and on maternal anemia in Benin. Am J Trop Med Hyg (2011) 1.80
Epitope mapping and topographic analysis of VAR2CSA DBL3X involved in P. falciparum placental sequestration. PLoS Pathog (2006) 1.76
Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. J Infect Dis (2009) 1.75
Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis (2008) 1.70
Influenza in Africa. PLoS Med (2009) 1.68
Import and spread of Panton-Valentine Leukocidin-positive Staphylococcus aureus through nasal carriage and skin infections in travelers returning from the tropics and subtropics. Clin Infect Dis (2011) 1.67
Occurrence of the Southeast Asian/South American SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania. J Infect Dis (2006) 1.64
Increased specific T cell cytokine responses in patients with active pulmonary tuberculosis from Central Africa. Microbes Infect (2005) 1.63
Depressed natural killer cell cytotoxicity against Plasmodium falciparum-infected erythrocytes during first pregnancies. Clin Infect Dis (2004) 1.61
Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria. Infect Immun (2004) 1.60
Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria. Antimicrob Agents Chemother (2002) 1.59
Increased prevalence of intestinal helminth infection during pregnancy in a Sub-Saharan African community. Wien Klin Wochenschr (2007) 1.58
Impact of increasing consultation fees on malaria in Africa. Wien Klin Wochenschr (2004) 1.56
Baculovirus-expressed constructs induce immunoglobulin G that recognizes VAR2CSA on Plasmodium falciparum-infected erythrocytes. Infect Immun (2006) 1.53
History and perspectives of medical research at the Albert Schweitzer Hospital in Lambaréné, Gabon. Wien Klin Wochenschr (2007) 1.52
Assessment of volume depletion in children with malaria. PLoS Med (2004) 1.51
Matrix metalloproteinases and their tissue inhibitors (TIMPs) in Plasmodium falciparum malaria: serum levels of TIMP-1 are associated with disease severity. J Infect Dis (2008) 1.51
Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA. Mol Microbiol (2006) 1.48
Expression of Plasmodium falciparum erythrocyte membrane protein 1 in experimentally infected humans. Malar J (2005) 1.48
Socio-economic status is inversely related to bed net use in Gabon. Malar J (2008) 1.46
In vitro selection of Plasmodium falciparum 3D7 for expression of variant surface antigens associated with severe malaria in African children. Parasite Immunol (2003) 1.44
Variant proteins of the Plasmodium falciparum RIFIN family show distinct subcellular localization and developmental expression patterns. Mol Biochem Parasitol (2007) 1.43
Adolescence as risk factor for adverse pregnancy outcome in Central Africa--a cross-sectional study. PLoS One (2010) 1.43
Effectiveness of rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis (2013) 1.41
Reduced cord blood immune effector-cell responsiveness mediated by CD4+ cells induced in utero as a consequence of placental Plasmodium falciparum infection. J Infect Dis (2005) 1.40
Evidence of decline of malaria in the general hospital of Libreville, Gabon from 2000 to 2008. Malar J (2009) 1.40
Plasmodium falciparum activates endogenous Cl(-) channels of human erythrocytes by membrane oxidation. EMBO J (2002) 1.40
Do African immigrants living in France have long-term malarial immunity? Am J Trop Med Hyg (2005) 1.39
A sub-family of common and highly conserved Plasmodium falciparum var genes. Mol Biochem Parasitol (2002) 1.38
Differential regulation of beta-chemokines in children with Plasmodium falciparum malaria. Infect Immun (2005) 1.37
Plasmodium falciparum parasites expressing pregnancy-specific variant surface antigens adhere strongly to the choriocarcinoma cell line BeWo. Infect Immun (2006) 1.37
Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob Agents Chemother (2002) 1.36
Variable adhesion abilities and overlapping antigenic properties in placental Plasmodium falciparum isolates. J Infect Dis (2004) 1.36
Can treatment of malaria be restricted to parasitologically confirmed malaria? A school-based study in Benin in children with and without fever. Malar J (2010) 1.36
Elevated nitric oxide production in children with malarial anemia: hemozoin-induced nitric oxide synthase type 2 transcripts and nitric oxide in blood mononuclear cells. Infect Immun (2004) 1.35
Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria. Antimicrob Agents Chemother (2006) 1.35
Nonspecific immunoglobulin M binding and chondroitin sulfate A binding are linked phenotypes of Plasmodium falciparum isolates implicated in malaria during pregnancy. Infect Immun (2003) 1.35
Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children. J Infect Dis (2004) 1.35
VAR2CSA expression on the surface of placenta-derived Plasmodium falciparum-infected erythrocytes. J Infect Dis (2008) 1.34
Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. J Infect Dis (2004) 1.34
Malaria in pregnancy before and after the implementation of a national IPTp program in Gabon. Am J Trop Med Hyg (2007) 1.34
A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS One (2009) 1.31
Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin. Trop Med Int Health (2007) 1.30
Malaria immunity in infants: a special case of a general phenomenon? Trends Parasitol (2004) 1.29
PfHRP2 and PfLDH antigen detection for monitoring the efficacy of artemisinin-based combination therapy (ACT) in the treatment of uncomplicated falciparum malaria. Malar J (2009) 1.29
Submicroscopic Plasmodium falciparum infections and multiplicity of infection in matched peripheral, placental and umbilical cord blood samples from Gabonese women. Trop Med Int Health (2004) 1.29
Recognition of variant Rifin antigens by human antibodies induced during natural Plasmodium falciparum infections. Infect Immun (2002) 1.27
Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon. Malar J (2008) 1.27
Community response to intermittent preventive treatment of malaria in infants (IPTi) delivered through the expanded programme of immunization in five African settings. Malar J (2009) 1.26
Evasion of immunity to Plasmodium falciparum malaria by IgM masking of protective IgG epitopes in infected erythrocyte surface-exposed PfEMP1. Proc Natl Acad Sci U S A (2011) 1.24
Geographical and temporal conservation of antibody recognition of Plasmodium falciparum variant surface antigens. Infect Immun (2004) 1.24
Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. Antimicrob Agents Chemother (2003) 1.24
Artesunate--amodiaquine combination therapy for falciparum malaria in young Gabonese children. Malar J (2007) 1.23
A novel domain cassette identifies Plasmodium falciparum PfEMP1 proteins binding ICAM-1 and is a target of cross-reactive, adhesion-inhibitory antibodies. J Immunol (2012) 1.23
The sickle cell trait is associated with enhanced immunoglobulin G antibody responses to Plasmodium falciparum variant surface antigens. J Infect Dis (2005) 1.23
The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa. PLoS One (2010) 1.22
Responses to Toll-like receptor ligands in children living in areas where schistosome infections are endemic. J Infect Dis (2004) 1.21
Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis (2010) 1.21
Molecular markers of resistance to sulphadoxine-pyrimethamine during intermittent preventive treatment of pregnant women in Benin. Malar J (2011) 1.21
Epidemiology of parasitic co-infections during pregnancy in Lambaréné, Gabon. Trop Med Int Health (2010) 1.20
Hierarchical, domain type-specific acquisition of antibodies to Plasmodium falciparum erythrocyte membrane protein 1 in Tanzanian children. Infect Immun (2010) 1.19